The study commencement is based on previous clinical safety and efficacy data, along with robust preclinical evidence.

Updated results from the INWORKS study “show the importance of adherence to the basic principles of radiation protection,” according to researchers.

We studied 1,910 intensively treated patients older than 60 years with AML and high-risk myelodysplastic syndrome (HR-MDS) from two cohorts (NCRI-AML18 and HOVON-SAKK). The median patient age was 67 ...

Donor lymphocyte infusion, both alone and in combination with azacitidine, restored CD34 levels in two-thirds of patients ...

Using iPS cells generated from a patient with a myeloid neoplasm caused by a rare chromosomal rearrangement between the MECOM and MYC genes, a team of researchers led by Associate Professor Yoshinori ...

Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome.

NDAQ:RIGL) Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML ...